The Gold Trade, May 24
Health Care: Drugs
AcelRx Pharmaceuticals Inc. (ACRX: NASDAQ)
$7.86 0.41 | 5.50%
05/24/13 - 03:59 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -33.36M | -20.10M | -14.34M | -20.12M |
| Operating Gains/Losses | 0.00 | 1.62M | 722.00K | -29.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 705.00K | 987.00K | -371.00K | -271.00K |
| (Decrease) Increase In Other Current Liabilities | 2.03M | 1.79M | -1.09M | -119.00K |
| (Increase) Decrease In Other Working Capital | 354.00K | -175.00K | -181.00K | -171.00K |
| Other Non-Cash Items | 4.28M | 321.00K | 2.68M | 672.00K |
| Net Cash From Continuing Operations | -24.58M | -15.29M | -12.22M | -19.42M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -24.58M | -15.29M | -12.22M | -19.42M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -826.00K | -2.02M | -4.00K | -111.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 14.96M | -29.58M | 4.76M | 8.62M |
| Issuance of Debt | 0.00 | 19.76M | 8.00M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 53.42M | 35.14M | 91.00K | 14.74M |
| Repayment of Long-Term Debt | -3.66M | -5.30M | -4.73M | -2.86M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 49.76M | 49.60M | 3.36M | 11.88M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 40.14M | 4.74M | -4.10M | 1.08M |
Portfolios with ACRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
Latest ACRX Headlines from TheStreet
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- 5 Stocks Insiders Are Stuffing in Their Stockings 12.12.12 | 12:12 pm
- Dunkin' Brands Prices IPO Above Range 07.26.11 | 07:07 pm
- IPO Lessons From Pandora 02.16.11 | 01:02 pm
- IPO Watch: 2011 02.16.11 | 01:02 pm
- Gaskins Warns on Speculative Pharma IPOs
02.02.11 | 08:02 am
Press Releases for ACRX
- AcelRx Pharmaceuticals To Present At The UBS Global Healthcare Conference - PR Newswire 05.16.13 | 03:05 pm
- AcelRx Pharmaceuticals To Hold First Quarter 2013 Financial Results Conference Call And Webcast On May 8, 2013 - PR Newswire 05.03.13 | 07:05 am
- AcelRx Pharmaceuticals Presents Positive Clinical Data For The Sufentanil NanoTab PCA System At ASRA Medical Meeting - PR Newswire 05.02.13 | 07:05 am
- Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint In Dose-Finding Phase 2 Clinical Trial - PR Newswire 04.24.13 | 07:04 am
- AcelRx Pharmaceuticals To Hold Fourth Quarter 2012 Financial Results Conference Call And Webcast On March 12, 2013 - PR Newswire 03.07.13 | 07:03 am
- AcelRx Top-line Data Show Primary Endpoint Achieved In Pivotal Phase 3 Study Of Sufentanil NanoTab PCA System For Post-Operative Pain In Major Open Abdominal Surgery Patients - PR Newswire 03.04.13 | 06:03 pm
- AcelRx Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.27.13 | 07:02 am
- AcelRx Pharmaceuticals Provides Clinical Trial Updates - PR Newswire 02.19.13 | 07:02 am
- AcelRx Appoints Adrian Adams To Board Of Directors As Chairman - PR Newswire 02.12.13 | 07:02 am
- AcelRx Pharmaceuticals Announces Exercise Of Option To Purchase Additional Shares - PR Newswire 12.14.12 | 12:12 pm
Partner Headlines for ACRX
- UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01 - Benzinga 04.08.13 | 09:04 am
- After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP - NASDAQ 03.12.13 | 06:03 pm
- AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts - Seeking Alpha 12.22.12 | 09:12 am
- FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain - Benzinga 11.15.12 | 08:11 am
- New IPO Filings And What's On The Horizon - Seeking Alpha 02.03.12 | 06:02 pm
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
